References
- Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020;92(4):418–423.
- Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17(3):181–192.
- WHO. Rolling updates on coronavirus disease (COVID-19). Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen. Accessed on Apr 2020.
- WHO. Coronavirus disease (COVID-19) pandemic. [cited 2020 Apr]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
- Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58–60.
- Cortegiani A, Ingoglia G, Ippolito M, et al. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020;57:279–283.
- Salvi R, Patankar P. Emerging pharmacotherapies for COVID-19. Biomed Pharmacother. 2020;128:110267.
- Bai Y, Yao L, Wei T, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA. 2020;323(14):1406–1407.
- Nguyen T, Duong Bang D, Wolff A. 2019 novel coronavirus disease (COVID-19): paving the road for rapid detection and point-of-care diagnostics. Micromachines. 2020;11(3):306.
- Corman VM, Landt O, Kaiser M, et al., Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3): 2000045.
- Amanat F, Krammer F. SARS-CoV-2 Vaccines: status report. Immunity. 2020;52(4):583–589.
- Taylor A, Foo SS, Bruzzone R, et al. Fc receptors in antibody-dependent enhancement of viral infections. Immunol Rev. 2015;268(1):340–364.
- Rosales-Mendoza S, Márquez-Escobar VA, González-Ortega O, et al. what does plant-based vaccine technology offer to the fight against COVID-19? Vaccines (Basel). 2020;8(2):183.
- Jackson TC, Patani BO, Ekpa DE. Nanotechnology in diagnosis: A review. Advances Nanoparticles. 2017;6(3):93–102.
- Qian C, Liu X, Xu Q, et al. Recent progress on the versatility of virus-like particles. Vaccines (Basel). 2020;8(1):139. .
- Rocchitta G, Spanu A, Babudieri S, et al. Enzyme biosensors for biomedical applications: strategies for safeguarding analytical performances in biological fluids. Sensors. 2016;16(6):780.
- Shi L, Sun Q, He J, et al. Development of SPR biosensor for simultaneous detection of multiplex respiratory viruses. Biomed Mater Eng. 2015;26:S2207–16.
- Cho SJ, Woo HM, Kim KS, et al. Novel system for detecting SARS coronavirus nucleocapsid protein using an ssDNA aptamer. J Biosci Bioeng. 2011;112(6):535–540.
- Park TJ, Lee SK, Yoo SM, et al. Development of reflective biosensor using fabrication of functionalized photonic nanocrystals. J Nanosci Nanotechnol. 2011;11(1):632–637.
- Ishikawa FN, Curreli M, Olson CA, et al. Importance of controlling nanotube density for highly sensitive and reliable biosensors functional in physiological conditions. ACS Nano. 2010;4(11):6914–6922. .
- Koo B, Hong KH, Jin CE, et al. Arch-shaped multiple-target sensing for rapid diagnosis and identification of emerging infectious pathogens. Biosens Bioelectron. 2018;119:79–85.
- Lee HY, Jeong H, Jung IY, et al. DhITACT: DNA hydrogel formation by isothermal amplification of complementary target in fluidic channels. Adv Mater. 2015;27(23):3513–3517.
- Jung IY, You JB, Choi BR, et al., Highly sensitive molecular detection platform for robust and facile diagnosis of middle east respiratory Syndrome (MERS) corona virus. Adv Healthc Mater. 5(17): 2168–2173. 2016.
- Komurian-Pradel F, Paranhos-Baccala G, Sodoyer M, et al. Quantitation of HCV RNA using real-time PCR and fluorimetry. J Virol Methods. 2016;95(1–2):111–119. .
- Na W, Nam D, Lee H, et al. Rapid molecular diagnosis of infectious viruses in microfluidics using DNA hydrogel formation. Biosens Bioelectron. 2018;108:9–13.
- CerTest Biotec. VIASURE real time PCR detection kits. [cited 2020 May]. Available from: https://www.certest.es/wp-content/uploads/2017/03/131-AF-Ficha-Mult.MERS-Coronavirus-ING_web.pdf.
- Corman VM, Ölschläger S, Wendtner CM, et al. Performance and clinical validation of the RealStar® MERS-CoV Kit for detection of Middle East respiratory syndrome coronavirus RNA. J Clin Virol. 2014;60(2):168–171.
- Hoy CF, Kushiro K, Yamaoka Y, et al. Rapid multiplex microfiber-based immunoassay for anti-MERS-CoV antibody detection. Sens Biosensing Res. 2019;26:100304.
- Layqah LA, Eissa S. An electrochemical immunosensor for the corona virus associated with the Middle East respiratory syndrome using an array of gold nanoparticle-modified carbon electrodes. Mikrochim Acta. 2019;186(4):224.
- Qiao J, Li Y, Wei C, et al. Rapid detection of viral antibodies based on multifunctional Staphylococcus aureus nanobioprobes. Enzyme Microb Technol. 2016;95:94–99.
- Hu W, Zhang Y, Yang H, et al. Simple and rapid preparation of red fluorescence and red color S. aureus derived nanobioparticles for pathogen detection. J Microbiol Methods. 2015;115:47–53.
- Park TJ, Lee SJ, Kim DK, et al. Development of label-free optical diagnosis for sensitive detection of influenza virus with genetically engineered fusion protein. Talanta. 2012;89:246–252.
- Jahanshahi P, Wei Q, Jie Z, et al. Kinetic analysis of IgM monoclonal antibodies for determination of dengue sample concentration using SPR technique. Bioengineered. 2017;8(3):239–247.
- Qiu G, Gai Z, Tao Y, et al. Dual-functional plasmonic photothermal biosensors for highly accurate severe acute respiratory syndrome coronavirus 2 detection. ACS Nano. 2020;14(5):5268–5277.
- Seo G, Lee G, Kim MJ, et al., Rapid detection of COVID-19 causative virus (SARS-CoV-2) in human nasopharyngeal swab specimens using field-effect transistor-based biosensor. ACS Nano. 2020;14(4): 5135–5142.
- FDA. Emergency Use Authorizations. [cited 2020 Apr]. Available from: https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations#covid19ivd.
- FDA. Coronavirus (COVID-19) Update: serological Tests. [cited 2020 Apr]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-serological-tests.
- FDA. Cellex qSARS-CoV-2 IgG/IgM Rapid Test. [cited 2020 Apr]. Available from: https://www.fda.gov/media/136625/download.
- FDA. DPP® COVID-19 IgM/IgG System. [cited 2020 Apr]. Available from: https://www.fda.gov/media/136963/download.
- U.S. Food and Drug Administration. VITROS immunodiagnostic product anti-SARS-CoV2 total reagent pack Ortho-Clinical Diagnosis, Inc. [cited 2020 Apr]. Available from: https://www.fda.gov/media/136970/download.
- Dynamiker. Clinical Value of IgG/IgM detection for COVID-19. [cited 2020 Apr]. Available from: http://en.dynamiker.com/index/index/news_info/aid/608.html.
- BioMedomics, Test for Life. COVID-19 IgM/IgG Rapid Test. [cited 2020 Apr]. Available from: https://www.biomedomics.com/products/infectious-disease/covid-19-rt/.
- RayBiotech Empowering your proteomics. Coronavirus (COVID-19) IgM/IgG Rapid Test Kit. [cited 2020 Apr]. Available from: https://www.raybiotech.com/covid-19-igm-igg-rapid-test-kit/.
- Sure Biotech. Coronavirus (COVID-19) Rapid Test. [cited 2020 Apr]. Available from: https://www.surebiotech.com/rapid-test/coronavirus-covid-19-rapid-test/#intro.
- SD Biosensor. Standard QCOVID-19 Ag. [cited 2020 Apr]. Available from: http://sdbiosensor.com/xe/product/7672.
- PharmACT HOLDING AG (INC.) SARS CoV-2 Rapid Test. [cited 2020 Apr]. Available from: https://pharmact-health.com/es/sars-cov-2-rapid-test/.
- Epitope Diagnistics, Inc. EDI™ Novel Coronavirus COVID-19 ELISA Kits. [cited 2020 Apr]. Available from: http://www.epitopediagnostics.com/covid-19-elisa.
- CD Creative Diagnostics. SARS-CoV-2 IgG ELISA Kit. [cited 2020 Apr]. Available from: https://www.creative-diagnostics.com/sars-cov-2-igg-elisa-kit-277909-466.htm.
- Shenzhen Yhlo Biotech CO. LTD. SARS-CoV-2 Solution. [cited 2020 Apr]. Available from: https://www.amp-asbach.de/index_files/flyer_cov2.pdf.
- Zhang W, Du RH, Li B, et al., Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect. 9(1): 386–389. 2020.
- Broughton JP, Deng X, Yu G, et al. CRISPR-Cas12-based detection of SARS-CoV-2. Nat Biotechnol. 2020;1-5.
- CorisBioConcept. COVID-19 Ag Respi-Strip. [cited 2020 Apr]. Available from: https://www.corisbio.com/pdf/Products/SARS-COVID-19_20200324.pdf.
- Ye S, Shao K, Li Z, et al. Antiviral activity of graphene oxide: how sharp edged structure and charge matter. ACS App Mater. 2015;7(38)21571–21579.
- Chen YN, Hsueh YH, Hsieh CT, et al. Antiviral activity of graphene–silver nanocomposites against non-enveloped and enveloped viruses. Int J Environ Res Public Health. 2016;13(4):430.
- Park S, Park HH, Kim SY, et al. Antiviral properties of silver nanoparticles on a magnetic hybrid colloid. Appl Environ Microbiol. 2014;80(8):2343–2350.
- Elechiguerra JL, Burt JL, Morones JR, et al. Interaction of silver nanoparticles with HIV-1. J Nanobiotechnology. 2005;3(1):6. .
- Lara HH, Ayala-Nuñez NV, Ixtepan-Turrent L, et al. Mode of antiviral action of silver nanoparticles against HIV-1. J Nanobiotechnology. 2010;8(1):1.
- Galdiero S, Falanga A, Vitiello M, et al. Silver nanoparticles as potential antiviral agents. Molecules. 2011;16(10):8894–8918.
- Loczechin A, Seron K, Barras A, et al. Functional carbon quantum dots as medical countermeasures to human coronavirus. ACS Appl Mater. 2019;11(46):42964–42974.
- Wang Y, Hu A. Carbon quantum dots: synthesis, properties and applications. J Mater Chem. 2014;2(34):6921–6939.
- Walls AC, Tortorici MA, Frenz B, et al. Glycan shield and epitope masking of a coronavirus spike protein observed by cryo-electron microscopy. Nat Struct Mol Biol. 2016;23(10):899.
- Du T, Liang J, Dong N, et al. Glutathione-capped Ag2S nanoclusters inhibit coronavirus proliferation through blockage of viral RNA synthesis and budding. ACS Appl Mater. 2018;10(5):4369–4378.
- Wang C, Wang Y, Xu L, et al. Facile aqueous‐phase synthesis of biocompatible and fluorescent Ag2S nanoclusters for bioimaging: tunable photoluminescence from red to near infrared. Small. 2012;8(20):3137–3142.
- Ting D, Dong N, Fang L, et al., Multisite inhibitors for enteric coronavirus: antiviral cationic carbon dots based on curcumin. ACS Appl Nano Mater. 1(10): 5451–5459. 2018. .
- Hewlings SJ, Kalman DS. Curcumin: a review of its effects on human health. Foods. 2017;6(10):92.
- Kocaadam B, Sanlier N. Curcumin, an active component of turmeric (Curcuma longa), and its effects on health. Crit Rev Food Sci Nutr. 2017;57(13):2889–2895.
- Zorofchian S, Abdul H, Hassandarvish P, et al. A review on antibacterial, antiviral, and antifungal activity of curcumin. BioMed Res Int. 2014;2014:1–12.
- Botequim D, Maia J, Lino MMF, et al. Nanoparticles and surfaces presenting antifungal, antibacterial and antiviral properties. Langmuir. 2012;28(20):7646–7656.
- Khanal M, Vausselin T, Barras A, et al. Phenylboronic-acid-modified nanoparticles: potential antiviral therapeutics. ACS Appl Mater. 2013;5(23):12488–12498.
- Lee JH, Ozorowski G, Ward AB. Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer. Science. 2016;351(6277):1043–1048.
- Liang JJ, Wei JC, Lee YL, et al. Surfactant-modified nanoclay exhibits an antiviral activity with high potency and broad spectrum. J Virol. 2014;88(8):4218–4228.
- Wang MC, Lin JJ, Tseng HJ, et al. Characterization, antimicrobial activities, and biocompatibility of organically modified clays and their nanocomposites with polyurethane. ACS Appl Mater. 2012;4(1):338–350.
- Miyako E, Nagata H, Hirano K, et al., Photoinduced antiviral carbon nanohorns. Nanotechnology. 19(7): 075106. 2008.
- Banerjee I, Douaisi MP, Mondal D, et al. Light-activated nanotube–porphyrin conjugates as effective antiviral agents. Nanotechnology. 2012;23(10):105101.
- Schneider JE, Tabatabaie T, Maidt L, et al. Potential mechanisms of photodynamic inactivation of virus by methylene blue I. RNA–protein crosslinks and other oxidative lesions in Qβ Bacteriophage. Photochem Photobiol. 1998;67(3):350–357.
- Bandyopadhyay AS, Garon J, Seib K, et al. Polio vaccination: past, present and future. Future Microbiol. 2015;10(5):791–808.
- Buchy P, Badur S. Who and when to vaccinate against influenza. Int J Infect Dis. 2020. 10.1016/j.ijid.2020.02.040
- Tseng CT, Sbrana E, Iwata-Yoshikawa N, et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PloS One. 2012;7(4). 10.1371/annotation/2965cfae-b77d-4014-8b7b-236e01a35492.
- Bhardwaj P, Bhatia E, Sharma S, et al. Advancements in Prophylactic and Therapeutic Nanovaccines. Acta Biomater. 2020;108:1–21.
- Gilca V, Sauvageau C, Boulianne N, et al. Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9-10 year-old girls according to 0-6 month schedule. Hum Vaccin Immunother. 2014;10(8):2438–2445. .
- Mortola E, Roy P. Efficient assembly and release of SARS coronavirus-like particles by a heterologous expression system. FEBS Lett. 2004;576(1–2):174–178.
- Ho Y, Lin PH, Liu CY, et al. Assembly of human severe acute respiratory syndrome coronavirus-like particles. Biochem Biophys Res Commun. 2004;318(4):833–838.
- Lu X, Chen Y, Bai B, et al. Immune responses against severe acute respiratory syndrome coronavirus induced by virus-like particles in mice. Immunology. 2007;122(4):496–502.
- Bai B, Hu Q, Hu H. Virus-like particles of SARS-like coronavirus formed by membrane proteins from different origins demonstrate stimulating activity in human dendritic cells. PLoS One. 2008;3(7):e2685.
- Lu B, Huang Y, Huang L, et al. Effect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in mice. Immunology. 2010;130(2):254–261.
- Liu YV, Massare MJ, Barnard DL, et al., Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV. Vaccine. 29(38): 6606–6613. 2011.
- Wang C, Zheng X, Gai W, et al., MERS-CoV virus-like particles produced in insect cells induce specific humoural and cellular imminity in rhesus macaques. Oncotarget. 8(8): 12686–12694. 2017.
- Kato T, Takami Y, Deo VK, et al. Preparation of virus-like particle mimetic nanovesicles displaying the S protein of Middle East respiratory syndrome coronavirus using insect cells. J Biotechnol. 2019;306:177–184.
- Kohyama S, Ohno S, Suda T, et al. Efficient induction of cytotoxic T lymphocytes specific for severe acute respiratory syndrome (SARS)-associated coronavirus by immunization with surface-linked liposomal peptides derived from a non-structural polyprotein 1a. Antivir Res. 2009;84(2):168–177.
- Ohno S, Kohyama S, Taneichi M, et al. Synthetic peptides coupled to the surface of liposomes effectively induce SARS coronavirus-specific cytotoxic T lymphocytes and viral clearance in HLA-A* 0201 transgenic mice. Vaccine. 2009;27(29):3912–3920. .
- Park BK, Lee SI, Bae JY, et al. Production of a Monoclonal Antibody targeting the M protein of MERS-CoV for detection of MERS-CoV using a synthetic peptide epitope formulated with a CpG–DNA–liposome complex. Int J Pept Res Ther. 2019;25(3):819–826.
- Park BK, Maharjan S, Lee SI, et al. Generation and characterization of a monoclonal antibody against MERS-CoV targeting the spike protein using a synthetic peptide epitope-CpG-DNA-liposome complex. BMB Rep. 2009;52(6):397.
- Clinical Trials. Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19). [cited 2020 Apr]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04283461?cond=COVID19&fund=01&draw=2&rank=9.
- Sekimukai H, Iwata-Yoshikawa N, Fukushi S, et al. Gold nanoparticle-adjuvanted S protein induces a strong antigen-specific IgG response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs. Microbiol Immunol. 2020;64(1):33–51.
- Stephen SL, Beales L, Peyret H, et al. Recombinant Expression of Tandem-HBc Virus-Like Particles (VLPs). Methods Mol Biol. 2018;1776:97–123.
- Fleming AB, Raabe V. Current studies of convalescent plasma therapy for COVID-19 may underestimate risk of antibody-dependent enhancement. J Clin Virol. 2020;127:104388.